This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance Of U.S. Patent For Treatment Of Skin Ulcers With Microcyn(R) Technology

PETALUMA, Calif., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates, today announced the issuance of new U.S. patent for the use of Microcyn® Technology in the treatment of skin ulcers. In this application, Microcyn Technology can be delivered to skin ulcers via washing, irrigation and soaking or through application of a wound dressing saturated in the Microcyn Technology. According to claims allowed by the patent examiner, the application of the Microcyn Technology via these methods will:

  • Reduce the microbial load of an infected diabetic foot ulcer;
  • Decrease the recurrence rate of an infected diabetic foot ulcer;
  • Decrease the likelihood of dehiscence of an infected diabetic foot ulcer;
  • Decrease the likelihood of amputation resulting from an infected diabetic foot ulcer;
  • Decrease the likelihood of systemic inflammatory response syndrome from an infected diabetic foot ulcer;
  • Decrease the likelihood of sepsis resulting from an infected diabetic foot ulcer.

Hoji Alimi, founder and CEO of Oculus said: "Skin ulcers, in varying presentations, are a significant challenge to the well being of millions. In fact, over six million Americans are afflicted each year with chronic wounds including arterial, diabetic, pressure and venous ulcers. The Microcyn Technology, cleared for the management of these ulcers by the FDA, is our first step into these large markets. This latest patent provides Oculus with the intellectual property protection necessary for an optimum return on our commercialization efforts, as well as those of our industry partners."  

The latest-issued patent joins a growing intellectual property estate (either owned or licensed to Oculus) that now includes 24 issued patents and 100+ pending applications directed to chemical compositions, apparatuses, methods of manufacturing and therapeutic uses.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs